Covid-19 vaccine Covaxin maker Bharat Biotech on Thursday said there was no external pressure on the firm to speed up its development. In a press release, the vaccine maker said with several hundred million doses administered worldwide, Covid-19 vaccine Co𝐆vaxin has demonstrated an excellent safety record with minimal adverse events and no vaccine associated cases detected for myocarditis or thrombocytopenia.
Refuting some media reports around the approvals for Covaxin, the vaccine maker said it condemns the "targeted narrative" against the vaccine put forth by a select few individuals and groups who have no expertise 🍰in vaccines or vaccinology, the firm said.
"There was no external pressure to accelerate development of Covaxin," it said, adding the pressure was all internal to develop a safe a♓nd effective vaccine for the Covid-19 pandemic, to save lives and livelihoods in India and globally.
Covaxin is one of the most highly studied Covid-19 vꦏaccines worldwide and was evaluated in approximately 20 pre-clinical studies, including three challenge trials and nine human clinical studies, more than any other Indian Covid-19 vaccine even as these trials have clearly demonstrated safety and efficacy of the vaccine, the com♎pany said.
The entire product development and clinical studies wꦰere executed as per global guidelines and submitted worldwide and the data from Covaxin has resulted in more than 20 publi𓂃cations, documenting every aspect of its development, Bharat Biotech further said.
(With PTI inputs)
